Literature DB >> 16205715

Therapeutics development for triplet repeat expansion diseases.

Nicholas A Di Prospero1, Kenneth H Fischbeck.   

Abstract

The underlying genetic mutations for many inherited neurodegenerative disorders have been identified in recent years. One frequent type of mutation is trinucleotide repeat expansion. Depending on the location of the repeat expansion, the mutation might result in a loss of function of the disease gene, a toxic gain of function or both. Disease gene identification has led to the development of model systems for investigating disease mechanisms and evaluating treatments. Examination of experimental findings reveals similarities in disease mechanisms as well as possibilities for treatment.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16205715     DOI: 10.1038/nrg1690

Source DB:  PubMed          Journal:  Nat Rev Genet        ISSN: 1471-0056            Impact factor:   53.242


  57 in total

Review 1.  Toward understanding Machado-Joseph disease.

Authors:  Maria do Carmo Costa; Henry L Paulson
Journal:  Prog Neurobiol       Date:  2011-11-23       Impact factor: 11.685

Review 2.  Epigenetic changes and non-coding expanded repeats.

Authors:  Masayuki Nakamori; Charles Thornton
Journal:  Neurobiol Dis       Date:  2010-02-18       Impact factor: 5.996

3.  Huntington's disease and neurogenesis: FGF-2 to the rescue?

Authors:  Albert R La Spada
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-05       Impact factor: 11.205

4.  Aggregation of scaffolding protein DISC1 dysregulates phosphodiesterase 4 in Huntington's disease.

Authors:  Motomasa Tanaka; Koko Ishizuka; Yoko Nekooki-Machida; Ryo Endo; Noriko Takashima; Hideyuki Sasaki; Yusuke Komi; Amy Gathercole; Elaine Huston; Kazuhiro Ishii; Kelvin Kai-Wan Hui; Masaru Kurosawa; Sun-Hong Kim; Nobuyuki Nukina; Eiki Takimoto; Miles D Houslay; Akira Sawa
Journal:  J Clin Invest       Date:  2017-03-06       Impact factor: 14.808

Review 5.  High throughput screening for neurodegeneration and complex disease phenotypes.

Authors:  Hemant Varma; Donald C Lo; Brent R Stockwell
Journal:  Comb Chem High Throughput Screen       Date:  2008-03       Impact factor: 1.339

6.  Reversible aggregation of PABPN1 pre-inclusion structures.

Authors:  Vered Raz; Tsion Abraham; Erik W van Zwet; Roeland W Dirks; Hans J Tanke; Silvère M van der Maarel
Journal:  Nucleus       Date:  2011 May-Jun       Impact factor: 4.197

Review 7.  Role of ubiquitin protein ligases in the pathogenesis of polyglutamine diseases.

Authors:  Priyanka Dikshit; Nihar Ranjan Jana
Journal:  Neurochem Res       Date:  2007-09-01       Impact factor: 3.996

Review 8.  Small molecules affecting transcription in Friedreich ataxia.

Authors:  Joel M Gottesfeld
Journal:  Pharmacol Ther       Date:  2007-08-09       Impact factor: 12.310

9.  Proteasomes cleave at multiple sites within polyglutamine tracts: activation by PA28gamma(K188E).

Authors:  Gregory Pratt; Martin Rechsteiner
Journal:  J Biol Chem       Date:  2008-03-13       Impact factor: 5.157

10.  Past, present and future therapeutics for cerebellar ataxias.

Authors:  D Marmolino; M Manto
Journal:  Curr Neuropharmacol       Date:  2010-03       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.